Pascal Soriot is stuck in a Chinese limbo. In recent months, the CEO of $205 billion drug giant AstraZeneca has seen his ...

Researchers examined pooled data from two clinical trials that enrolled patients with low- or intermediate-grade ductal ...

New documents have investigators questioning inconsistencies and omissions in data reporting in the PLATO trial, building on ...

SAN ANTONIO -- The addition of palbociclib (Ibrance) to current standard-of-care therapy following induction chemotherapy ...

Among more than 5,000 patients followed for a median of roughly 8 years, bilateral risk-reducing mastectomy (RRM) was ...

AstraZeneca and Daiichi Sankyo shared the pooled analysis behind the refiling of their TROP2 antibody-drug conjugate (ADC) ...

In a report released on December 11, David Evans from Kepler Capital maintained a Hold rating on AstraZeneca (AZN – Research Report), with a ...

A new report questions the efficacy of a drug approved by the FDA to help precent heart attack and stroke in people with a ...

The AstraZeneca PLC ADR AZN slid 0.68% to $66.94 Thursday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ Composite Index COMP falling 0.66% to 19,902.84 ...

Two days after the FDA revealed that it had halted enrollment in trials of respiratory syncytial virus (RSV) vaccines that ...

Shares of AstraZeneca PLC AZN inched up 0.28% to £105.68 Thursday, on what proved to be an all-around great trading session for the stock market, with the FTSE 100 Index UKX rising 0.12% to 8,311.76.

AstraZeneca & Merck announce OlympiA phase 3 trial of Lynparza demonstrated clinically meaningful prolonged survival benefit in early breast cancer: Rahway, New Jersey Friday, Dec ...